A Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate transporter 1 inhibitor (MCT1) in patients with advanced cancer

Trial Profile

A Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate transporter 1 inhibitor (MCT1) in patients with advanced cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs AZD 3965 (Primary)
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Gastric cancer; Lymphoma; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 12 Jul 2018 Planned number of patients changed from 64 to 63.
    • 12 Jul 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2019.
    • 23 Apr 2018 As per the results presented at the 16th International Congress on Targeted Anticancer Therapies, part 2 of this trial is open to recruitment in patients with diffuse large B cell lymphoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top